AnaptysBio Inc. (ANAB) Financial Statements (2026 and earlier)

Company Profile

Business Address 10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments311,638385,373390,904441,241548,097393,653
Cash and cash equivalent238,196123,08035,96571,308495,729250,456
Short-term investments73,442262,293354,939369,93352,368143,197
Receivables33,85040,7656,8511,419876 
Prepaid expense      200
Other undisclosed current assets4,7625,7389,0804,5454,9032,708
Total current assets:350,250431,876406,835447,205553,876396,561
Noncurrent Assets
Operating lease, right-of-use asset12,51914,38316,17417,89819,558 
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization1,3701,8492,0982,0892,2831,783
Long-term investments and receivables  35,47027,026142,93567,09717,546
Long-term investments  35,47027,026142,93567,09717,546
Restricted cash and investments      60
Other noncurrent assets256256256256256602
Total noncurrent assets:14,14551,95845,554163,17889,19419,991
TOTAL ASSETS:364,395483,834452,389610,383643,070416,552
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities36,54543,50335,66524,41714,59419,479
Accounts payable3,8714,0024,6982,7841,7414,217
Accrued liabilities32,67439,50130,96721,63312,85315,262
Other liabilities      342
Other undisclosed current liabilities2,0801,9251,7771,6371,505 
Total current liabilities:38,62545,42837,44226,05416,09919,821
Noncurrent Liabilities
Long-term debt and lease obligation:     19,450 
Liabilities, other than long-term debt12,03214,11216,03717,813  
Operating lease, liability12,03214,11216,03717,81319,450 
Total noncurrent liabilities:12,03214,11216,03717,81338,900 
Total liabilities:50,65759,54053,47943,86754,99919,821
Equity
Equity, attributable to parent37,21070,86888,103262,103356,428396,731
Common stock283027292827
Additional paid in capital809,765829,860702,969717,797678,575660,665
Accumulated other comprehensive income (loss)(24)305(797)(5,246)(422)(4)
Accumulated deficit(772,559)(759,327)(614,096)(450,477)(321,753)(263,957)
Total equity:37,21070,86888,103262,103356,428396,731
Other undisclosed liabilities and equity276,528353,426310,807304,413231,643 
TOTAL LIABILITIES AND EQUITY:364,395483,834452,389610,383643,070416,552

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues234,60391,28017,15710,28763,17575,000
Gross profit:234,60391,28017,15710,28763,17575,000
Operating expenses(186,707)(206,229)(181,568)(125,441)(119,989)(98,879)
Operating income (loss):47,896(114,949)(164,411)(115,154)(56,814)(23,879)
Nonoperating income (expense)(60,964)(30,279)788(13,546)(982)3,948
Loss from continuing operations before income taxes:(13,068)(145,228)(163,623)(128,700)(57,796)(19,931)
Income tax expense (benefit)(164)(3)4(24)  
Loss from continuing operations:(13,232)(145,231)(163,619)(128,724)(57,796)(19,931)
Loss before gain (loss) on sale of properties:(57,796)(19,931)
Net loss available to common stockholders, diluted:(13,232)(145,231)(163,619)(128,724)(57,796)(19,931)

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(13,232)(145,231)(163,619)(128,724)(57,796)(19,931)
Comprehensive loss:(13,232)(145,231)(163,619)(128,724)(57,796)(19,931)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(329)1,1024,449(4,824)(418)(342)
Comprehensive loss, net of tax, attributable to parent:(13,561)(144,129)(159,170)(133,548)(58,214)(20,273)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: